SCHEMBL6984615

SCHEMBL6984615

CSCC[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)N1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 3/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CCR1 P32246 1/20 0.46
UBE2N P61088 1/20 0.45
TGM2 P21980 2/20 0.44
TGM6 O95932 1/20 0.44
F13A1 P00488 1/20 0.44
TGM1 P22735 1/20 0.44
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
AKR1C3 P42330 1/20 0.41
MC4R P32245 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982389 0.95 TGM2 (0.47) KMT2AALDH1A1MEN1KDM4EGAA
SCHEMBL6981151 0.86 TGM2 (0.45) KMT2AALDH1A1MEN1TGM2TGM6
SCHEMBL6985309 0.86 CAPN1 (0.54) KMT2AALDH1A1MEN1KDM4EGAA
SCHEMBL6979028 0.82 SMN1; SMN2 (0.49) KMT2AALDH1A1MEN1GAACCR1
SCHEMBL6979020 0.82 SMN1; SMN2 (0.49) KMT2AALDH1A1MEN1GAACCR1
SCHEMBL6978563 0.81 CCR1 (0.50) KMT2AALDH1A1CCR1SMN1; SMN2L3MBTL1
SCHEMBL6981698 0.79 CCR1 (0.47) KMT2AALDH1A1CCR1SMN1; SMN2AKR1C3
SCHEMBL8405526 0.79 SMN1; SMN2 (0.42) KMT2AALDH1A1MEN1GAATGM2
SCHEMBL6981807 0.77 SMN1; SMN2 (0.43) KMT2AALDH1A1MEN1GAACCR1
SCHEMBL6981803 0.77 ADAM10 (0.40) KMT2AALDH1A1MEN1TGM2TGM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed